Molecular Oncology

Papers
(The TQCC of Molecular Oncology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Issue Information212
106
Issue Information94
91
Corrigendum to: Small proline‐rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage‐induced apoptosis85
Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors78
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer77
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF175
Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation67
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity63
An arms‐race against resistance: leukemic stem cells and lineage plasticity63
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM55
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma55
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer54
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas53
Correction to “Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition”52
Correction to “SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression”48
NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy42
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2+ mononuclear phagocyte differentiation in liver cancer42
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer40
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1NDRG1 deregulation40
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 439
Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo38
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy38
Cancer‐associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T‐cell suppression36
TGFβ selects for pro‐stemness over pro‐invasive phenotypes during cancer cell epithelial–mesenchymal transition35
Precision Cancer Medicine 2.0—Oncology in the postgenomic era35
Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread34
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities34
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PDL1 immunotherapy in arm A of the NSGO33
Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer33
Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma33
Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling32
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis32
Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection32
ERK signaling controls productive HIF‐1 binding to chromatin and cancer cell adaptation to hypoxia through HIF‐1α interaction with NPM131
Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment30
Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia‐inducible factor‐1α in colorectal cancer29
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system29
Issue Information29
RETRACTION: Long Noncoding RNA ZNF667‐AS1 Reduces Tumor Invasion and Metastasis in Cervical Cancer by Counteracting Microrna‐93‐3p‐Dependent PEG3 Downregulation28
Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor28
Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma28
Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC28
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models28
Academia and society should join forces to make anti‐cancer treatments more affordable27
Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer27
Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis26
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia26
RNA polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells26
Hijacking the BAF complex: the mechanistic interplay of ARID1A and EWS::FLI1 in Ewing sarcoma25
Correction to: Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C25
Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration25
ANGPTL2‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion24
New retinoblastoma (RB) drug delivery approaches: anti‐tumor effect of atrial natriuretic peptide (ANP)‐conjugated hyaluronic‐acid‐coated gold nanoparticles for intraocular treat24
Germline variants in CDKN2A wild‐type melanoma prone families24
Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer24
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients24
DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC23
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer23
Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T‐cell receptor sequencing23
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma23
Cancer cachexia: biomarkers and the influence of age23
Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion23
Issue Information23
T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinoma23
The transcribed ultraconserved region uc.160+ enhances processing and A‐to‐I editing of the miR‐376 cluster: hypermethylation improves glioma prognosis23
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers22
Retraction statement: Consistency analysis of microRNA‐arm expression reveals microRNA‐369‐5p/3p as tumor suppressors in gastric cancer22
Replenishing co‐downregulated miR‐100‐5p and miR‐125b‐5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption22
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK<22
The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival22
Issue Information22
Cotargeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling22
LncRNA miR205HG hinders HNRNPA0 translation: anti‐oncogenic effects in esophageal carcinoma22
Sustained cancer‐relevant alternative RNA splicing events driven by PRMT5 in high‐risk neuroblastoma22
NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR‐Akt feedback loop that activates autophagy22
21
Rodent models of tumours of the central nervous system21
Issue Information21
Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR<21
Tetraploidy‐linked sensitization to CENP‐E inhibition in human cells21
Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment20
Post‐prostatic‐massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate‐cancer‐typical microRNAs and activate proto‐oncogenes20
Correction to “The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion”20
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies20
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential20
Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers19
FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas19
Cancer outcome research – a European challenge Part II: Opportunities and priorities19
Long noncoding RNAs with peptide‐encoding potential identified in esophageal squamous cell carcinoma: KDM4A‐AS1‐encoded peptide weakens cancer cell viability and migratory capacity19
DNA repair as a shared hallmark in cancer and ageing19
Abstracts19
MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness19
Targeting protein folding in N‐Myc‐driven medulloblastoma19
Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR)19
Cancer as an infective disease: the role of EVs in tumorigenesis19
Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models19
SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner19
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma19
Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors18
MicroRNAs in blood act as biomarkers of colorectal cancer and indicate potential therapeutic targets18
Assay‐agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple‐negative breast cancer17
KRAS inhibitors: going noncovalent17
A rapid, multiplex digital PCR assay to detect gene variants and fusions in non‐small cell lung cancer17
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients17
Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer17
CHML is an NRF2 target gene that regulates mTOR function17
Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience16
Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study16
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models16
A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL‐13Rα2‐mediated JNK‐AP‐1 signals16
Assembly of glioblastoma tumoroids and cerebral organoids: a 3Din vitro model for tumor cell invasion16
Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation16
Lung cancer cells expressing a shortened CDK16 3′UTR escape senescence through impaired miR‐485‐5p targeting16
Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach16
Microglia and macrophages in glioblastoma: landscapes and treatment directions15
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis15
Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay15
Issue Information15
USP35 mitigates endoplasmic reticulum stress‐induced apoptosis by stabilizing RRBP1 in non‐small cell lung cancer15
Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial15
15
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B115
Retraction Statement: Circ‐TCF4.85 silencing inhibits cancer progression through microRNA‐486‐5p‐targeted inhibition of ABCF2 in hepatocellular carcinoma15
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance15
cAMP‐phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression15
Targeting cellular senescence to combat cancer and ageing15
Liver X receptors induce antiproliferative effects in basal‐like breast cancer15
Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer15
Issue Information15
Elucidating prognostic significance of purine metabolism in colorectal cancer through integrating data from transcriptomic, immunohistochemical, and single‐cell RNA sequencing analysis14
Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial14
The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma14
Issue Information14
Issue Information14
Characterization of fragment sizes, copy number aberrations and 4‐mer end motifs in cell‐free DNA of hepatocellular carcinoma for enhanced liquid biopsy‐based cancer detection14
PP2A‐based triple‐strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells14
Lipid metabolism in B cell biology14
Protein palmitoylation in cancer: molecular functions and therapeutic potential14
Issue Information14
Current status of precision oncology in adult glioblastoma14
Targeting senescence as an anticancer therapy14
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma14
Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells14
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma14
The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma14
Expression of Concern: T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma14
From bedside to portable and wearable: development of a conformable ultrasound patch for deep breast tissue imaging13
Copy number variations contribute to malignant tumor development in children with serious birth defects13
Immune evasion: An imperative and consequence of MYC deregulation13
ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma13
Metabolism in the tumor cell and beyond13
Thioredoxin‐interacting protein (TXNIP) is a substrate of the NEDD4‐like E3 ubiquitin‐protein ligase WWP1 in cellular redox state regulation of acute myeloi13
Enhanced reversal of ABCG2‐mediated drug resistance by replacing a phenyl ring in baicalein with a meta‐carborane13
Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice13
SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma13
SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy13
Postbiotics of Lacticaseibacillus paracaseiCECT 9610 and Lactiplantibacillus plantarumCECT 9608 attenuates store‐operated calcium entry and FAK phosphory13
CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma13
Immune escape of colorectal tumours via local LRH‐1/Cyp11b1‐mediated synthesis of immunosuppressive glucocorticoids12
Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia12
Fragment‐based drug discovery—the importance of high‐quality molecule libraries12
The invariant chain CD74 protein is a cell surface binding partner of TIMP‐1 in breast cancer cells12
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation12
GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL12
Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β‐catenin signaling and tumor growth12
12
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients12
Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome12
Issue Information12
11
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities11
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype11
Identifying the personalized driver gene sets maximally contributing to abnormality of transcriptome phenotype in glioblastoma multiforme individuals11
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy11
Thermal proteome profiling and proteome analysis using high‐definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next‐generation galeterone analog VNPP433‐3β i11
Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study11
Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade11
Lipopolysaccharide from the commensal microbiota of the breast enhances cancer growth: role of S100A7 and TLR411
Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location11
11
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAFV600E mutated colorectal cancer—results from the FIRE‐4.5 study11
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework11
The roles and applications of extracellular vesicles in cancer11
miR‐200a/b/‐429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer11
VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer10
Viral mimicry evasion: a new role for oncogenic KRAS mutations10
Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis10
Investigation of somatic mutation profiles and tumor evolution of primary oropharyngeal cancer and sequential lymph node metastases using multiregional whole‐exome sequencing10
Transcriptomic pan‐cancer analysis using rank‐based Bayesian inference10
LIM domain‐containing protein Ajuba inhibits chemotherapy‐induced apoptosis by negatively regulating p53 stability in colorectal cancer cells10
Identification and targeting of a HES1‐YAP1‐CDKN1C functional interaction in fusion‐negative rhabdomyosarcoma10
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study10
Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy10
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration10
Deciphering metabolic crosstalk in context: lessons from inflammatory diseases10
Nicotinamide (niacin) supplement increases lipid metabolism and ROS‐induced energy disruption in triple‐negative breast cancer: potential for drug repositioning as an anti‐tumor agent10
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer10
Resistance prediction in high‐grade serous ovarian carcinoma with neoadjuvant chemotherapy using data‐independent acquisition proteomics and an ovary‐specific spectral library10
Interferon regulatory factor 4 modulates epigenetic silencing and cancer‐critical pathways in melanoma cells10
Bovine meat and milk factor protein expression in tumor‐free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival10
Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment10
Enhancing therapeutic efficacy in triple‐negative breast cancer and melanoma: synergistic effects of modulated electro‐hyperthermia (mEHT) with NSAIDs especially COX‐2 inhibition in in vivo mod10
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?10
10
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives10
Integrated analysis of racial disparities in genomic architecture identifies a trans‐ancestry prognostic subtype in bladder cancer10
Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis10
Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity10
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long‐term follow‐up of the SweBCG91RT rand10
Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTOR10
Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product10
High CD34 surface expression in BCP‐ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion9
Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance9
Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction9
Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis9
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications9
Proximity proteomics reveals role of Abelson interactor 1 in the regulation of TAK1/RIPK1 signaling9
hnRNP‐A1 binds to the IRES of MELOE‐1 antigen to promote MELOE‐1 translation in stressed melanoma cells9
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care9
Screening of an annexin‐A2‐targeted heptapeptide for pancreatic adenocarcinoma localization9
The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging‐related disease9
Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients9
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer9
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers9
Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma9
Sortilin‐related receptor is a druggable therapeutic target in breast cancer9
PP2A methylesterase PME‐1 suppresses anoikis and is associated with therapy relapse of PTEN‐deficient prostate cancers9
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management9
Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study9
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib9
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials9
PPM1D activity promotes the replication stress caused by cyclin E1 overexpression9
Overexpression of the pro‐protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling9
Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells9
0.069064140319824